129 related articles for article (PubMed ID: 11426554)
1. Effectiveness of interferon-alfa and mid-cycle chemotherapy added to an anthracycline-based regimen in the treatment of aggressive non-Hodgkin's lymphoma.
Enschede SH; Shahidi H; Venugopal P; Riley MB; Huang R; Jajeh A; Preisler HD; Gregory SA
Leuk Lymphoma; 2001 Jan; 40(3-4):325-34. PubMed ID: 11426554
[TBL] [Abstract][Full Text] [Related]
2. Autologous stem cell transplantation following induction therapy with an anthracycline-based regimen including interferon-alpha for low-grade non-Hodgkin's lymphoma.
Enschede SH; Porter C; Venugopal P; Gregory SA
Clin Adv Hematol Oncol; 2004 Apr; 2(4):229-33. PubMed ID: 16163187
[TBL] [Abstract][Full Text] [Related]
3. Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma.
Smalley RV; Andersen JW; Hawkins MJ; Bhide V; O'Connell MJ; Oken MM; Borden EC
N Engl J Med; 1992 Nov; 327(19):1336-41. PubMed ID: 1406835
[TBL] [Abstract][Full Text] [Related]
4. Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group.
Hagenbeek A; Carde P; Meerwaldt JH; Somers R; Thomas J; De Bock R; Raemaekers JM; van Hoof A; De Wolf-Peeters C; van Glabbeke M
J Clin Oncol; 1998 Jan; 16(1):41-7. PubMed ID: 9440721
[TBL] [Abstract][Full Text] [Related]
5. A prospective randomized study of Chop versus Chop plus alpha-2B interferon in patients with intermediate and high grade non-Hodgkin's lymphoma: the International Oncology Study Group NHL1 Study .
Giles FJ; Shan J; Advani SH; Akan H; Aydogdu I; Aziz Z; Azim HA; Bapsy PP; Buyukkececi F; Chaimongkol B; Chen PM; Cheong SK; Ferhanoglu B; Hamza R; Khalid HM; Intragumtornchai T; Kim SW; Kim SY; Koc H; Kumar L; Kumar R; Lei KI; Lekhakula A; Muthalib A; Patel M; Poovalingam VP; Prayoonwiwat W; Rana F; Reksodiputro AH; Ruff P; Sagar TG; Schwarer AP; Song HS; Suh CW; Suharti C; Supindiman I; Tee GY; Thamprasit T; Villalon AH; Wickham NR; Wong JE; Yalcin A; Jootar S;
Leuk Lymphoma; 2000 Dec; 40(1-2):95-103. PubMed ID: 11426633
[TBL] [Abstract][Full Text] [Related]
6. Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization.
Arranz R; García-Alfonso P; Sobrino P; Zamora P; Carrión R; García-Laraña J; Pérez G; López J; Lavilla E; Lozano M; Rayón C; Colomer R; Barón MG; Flores E; Pérez-Manga G; Fernández-Rañada JM
J Clin Oncol; 1998 Apr; 16(4):1538-46. PubMed ID: 9580385
[TBL] [Abstract][Full Text] [Related]
7. Final analysis of the ECOG I-COPA trial (E6484) in patients with non-Hodgkin's lymphoma treated with interferon alfa (IFN-alpha2a) plus an anthracycline-based induction regimen.
Smalley RV; Weller E; Hawkins MJ; Oken MM; O'Connell MJ; Haase-Statz S; Borden EC
Leukemia; 2001 Jul; 15(7):1118-22. PubMed ID: 11455982
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.
Vose JM; Link BK; Grossbard ML; Czuczman M; Grillo-Lopez A; Gilman P; Lowe A; Kunkel LA; Fisher RI
J Clin Oncol; 2001 Jan; 19(2):389-97. PubMed ID: 11208830
[TBL] [Abstract][Full Text] [Related]
9. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group.
Unterhalt M; Herrmann R; Tiemann M; Parwaresch R; Stein H; Trümper L; Nahler M; Reuss-Borst M; Tirier C; Neubauer A; Freund M; Kreuser ED; Dietzfelbinger H; Bodenstein H; Engert A; Stauder R; Eimermacher H; Landys K; Hiddemann W
Leukemia; 1996 May; 10(5):836-43. PubMed ID: 8656680
[TBL] [Abstract][Full Text] [Related]
10. Mitoxantrone and fludarabine in the treatment of patients with non-Hodgkin's lymphoma failing primary therapy with a doxorubicinor mitoxantrone-containing regimen.
Gregory SA; Vose J; Modiano M; Kraemer K; Rifkin R; Rubin A; Menduni T; Ghalie R
Leuk Lymphoma; 2001 Jan; 40(3-4):315-24. PubMed ID: 11426553
[TBL] [Abstract][Full Text] [Related]
11. Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809.
Fisher RI; Dana BW; LeBlanc M; Kjeldsberg C; Forman JD; Unger JM; Balcerzak SP; Gaynor ER; Roy V; Miller T
J Clin Oncol; 2000 May; 18(10):2010-6. PubMed ID: 10811664
[TBL] [Abstract][Full Text] [Related]
12. A cooperative study of epirubicin with cyclophosphamide, vincristine and prednisone (CEOP) in non-Hodgkin's lymphoma.
Lambertenghi Deliliers G; Butti C; Baldini L; Ceriani A; Lombardi F; Luoni M; Montalbetti L; Pavia G; Pinotti G; Pogliani E
Haematologica; 1995; 80(4):318-24. PubMed ID: 7590500
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of fludarabine and alpha-interferon in patients with low-grade non-Hodgkin's lymphoma.
Morris GJ; Millenson MM; Padavic-Shaller K; Wang H; Rogatko A; Clyde J; Boyd RL; Yeslow G; Halbherr T; Schilder RJ; Smith MR
Haematologica; 2004 Dec; 89(12):1484-91. PubMed ID: 15590399
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II study of cyclophosphamide, carboplatin, and etoposide and autologous hematopoietic stem-cell transplantation with posttransplant interferon alfa-2b for patients with lymphoma and Hodgkin's disease.
Schenkein DP; Dixon P; Desforges JF; Berkman E; Erban JK; Ascensao JL; Miller KB
J Clin Oncol; 1994 Nov; 12(11):2423-31. PubMed ID: 7964959
[TBL] [Abstract][Full Text] [Related]
15. ACOD, a modified CHOP regimen for elderly patients with aggressive non-Hodgkin's lymphoma.
Martinelli G; Ferrucci PF; Mingrone W; Cocorocchio E; Conconi A; Peccatori FA; De Luzio K; Santoro P; Mazzetta C; Zucca E; Cavalli F
Leuk Lymphoma; 2003 May; 44(5):801-6. PubMed ID: 12802917
[TBL] [Abstract][Full Text] [Related]
16. Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma.
Hendry L; Bowen A; Matutes E; Swansbury J; Catovsky D
Leuk Lymphoma; 2004 May; 45(5):945-50. PubMed ID: 15291353
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of cyclophosphamide,epirubicin, vincristine, prednisone, and etoposide (CEOP-E) for aggressive non-Hodgkin 's lymphoma.
Kim JG; Sohn SK; Kim DH; Baek JH; Park TI; Lee KB
J Korean Med Sci; 2004 Dec; 19(6):820-5. PubMed ID: 15608392
[TBL] [Abstract][Full Text] [Related]
18. Liposomal daunorubicin (DaunoXome) in combination with cyclophosphamide, vincristine and prednisolone (COP-X) as salvage therapy in poor-prognosis non-Hodgkins lymphoma.
McBride NC; Cavenagh JD; Ward MC; Grant I; Schey S; Gray A; Hughes A; Mills MJ; Cervi P; Newland AC; Kelsey SM
Leuk Lymphoma; 2001 Jun; 42(1-2):89-98. PubMed ID: 11699226
[TBL] [Abstract][Full Text] [Related]
19. Treatment of low-grade non-Hodgkin's lymphoma by cytoreductive chemotherapy with prednimustine/mitoxantrone followed by interferon alpha-2b maintenance: results of a clinical phase II study.
Hiddemann W; Unterhalt M; Koch P; Nahler M; van de Loo J
Semin Oncol; 1990 Dec; 17(6 Suppl 10):20-3. PubMed ID: 2259919
[TBL] [Abstract][Full Text] [Related]
20. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity.
Gómez H; Mas L; Casanova L; Pen DL; Santillana S; Valdivia S; Otero J; Rodriguez W; Carracedo C; Vallejos C
J Clin Oncol; 1998 Jul; 16(7):2352-8. PubMed ID: 9667250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
